drugset / Trial / NCT02493322

Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control

NCT02493322

Phase 3 Withdrawn EMS
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

Timeline

Start
Primary completion
2025-06-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Chlorthalidone Other / unclassified 12.5 mg
Subject Chlorthalidone Other / unclassified 25 mg
Subject Hydrochlorothiazide Unknown 12.5 mg
Subject Olmesartan Other / unclassified 20 mg